CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CDNA - CareDx, Inc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.00
DETAILS
HIGH:
$28.00
LOW:
$28.00
MEDIAN:
$28.00
CONSENSUS:
$28.00
DOWNSIDE:
2.64%
Stock News
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearan.
CareDx's CEO Sells 17K Shares
The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.
CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overvalued
On June 16, 2026, CareDx Inc (CDNA) shares fell by 3.4% to a current price of $23.22. The stock has experienced a 52-week range with a high of $24.85 and a low
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Nephrology (JASN). The se.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baron Discovery Fund Q1 2026: Who Moved The Needle
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.
CareDx Announces Dismissal of 2021 Qui Tam Suit
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. Ther.
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggreg.
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito.
CareDx Announces First Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m.
Price Targets
CareDx price target raised to $28 from $26 at BTIG
$28.00
(was $21.91)
BTIG
CareDx, Inc (CDNA) PT Raised to $26 at BTIG
$26.00
(was $18.46)
Sung Ji Nam
·
BTIG
CareDx downgraded to Hold from Buy at Craig-Hallum
$26.00
(was $19.81)
Craig-Hallum
CareDx price target raised to $18 from $14 at Wells Fargo
$18.00
(was $20.57)
Brandon Couillard
·
Wells Fargo
CareDx price target lowered to $25 from $26 at H.C. Wainwright
$25.00
(was $21.13)
H.C. Wainwright
CareDx, Inc (CDNA) PT Lowered to $35 at BTIG
$35.00
(was $22.90)
Sung Ji Nam
·
BTIG
CareDx upgraded to Buy from Neutral at BTIG
$40.00
(was $33.00)
Mark Massaro
·
BTIG
CareDx price target raised to $40 from $32 at Craig-Hallum
$40.00
(was $32.98)
Bill Bonello
·
Craig-Hallum
CareDx price target raised to $32 from $22 at Craig-Hallum
$32.00
(was $19.99)
Bill Bonello
·
Craig-Hallum
Stephens Reiterates Overweight Rating on CareDx, Inc (CDNA)
$15.00
(was $8.29)
Mason Carrico
·
Stephens
Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $29
$29.00
(was $16.26)
Goldman Sachs
Stephens & Co. Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $50
$50.00
(was $31.72)
Stephens